TAP Licenses Prevacid To Novartis For 2009 Switch
This article was originally published in The Tan Sheet
Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20
You may also be interested in...
Novartis Consumer Health remains "very committed to the Rx-to-OTC switch" of TAP Pharmaceutical Products' proton pump inhibitor Prevacid, the firm told "The Tan Sheet" March 20. Novartis reaffirmed its commitment to switching the hearthburn drug after Japanese drug firm Takeda announced March 19 it obtained a 100 percent stake in TAP when it bought out Abbott's 50 percent share of the joint venture. According to terms of the deal, Takeda will get the rights to Rx Prevacid. TAP will be integrated into Takeda's existing U.S. subsidiaries, which will establish Takeda America Holdings, the Japanese company says. Novartis Consumer Healthcare acquired the trademark and intellectual property rights for OTC Prevacid (lansoprazole) from TAP in December 2005, at which time Novartis announced plans for a switch in 2009 when the drug's patent expires (1"The Tan Sheet" Jan. 2, 2006, p. 6)...
Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch
Novartis sees further promotion of Excedrin Migraine as an "unexploited opportunity" to expand the brand's presence and grow the firm's OTC category